Ellen Romich, MD, MSCE, examines associated vasculitis relapse and which markers sig examines associated vasculitis relapse ...

Source: Getty Images A EULAR task force revised guidelines to reflect findings from randomized clinical trials that were published since the last update in 2016. A task force of the European Alliance ...

Despite the frequency of coronary artery calcification among patients with antineutrophil cytoplasmic antibody-associated vasculitis, only 25% were using statins. A significant percentage of patients ...

Please provide your email address to receive an email when new articles are posted on . “Today is a momentous day in the history of ChemoCentryx; the culmination of decades of effort aimed at offering ...

An investigational C5a receptor inhibitor, avacopan, was effective as a steroid-sparing induction treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in a phase III trial ...

Please provide your email address to receive an email when new articles are posted on . Despite an ever-growing array of potential candidate biomarkers for antineutrophil cytoplasmic ...

A data-driven subclassification of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis has identified five distinct clusters with varying degrees of kidney involvement and systemic ...

Maintaining remission in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who have kept their autoantibodies in check after at least 2 years on rituximab therapy has ...

Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis, or AAV, causes inflammation of the blood vessels and can affect many parts of the body, including multiple organs. Because of this, ...

Wegener's granulomatosis, microscopic polyangiitis (MPA), Churg–Strauss syndrome, and primary pauci-immune crescentic glomerulonephritis are associated with circulating anti-neutrophil cytoplasmic ...

Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a severe condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) ...

Avacopan, which targets a receptor that attracts the cells that cause inflammation, was shown to be more effective at keeping patients in remission for a year than prednisone. A Phase 3 clinical trial ...